Natural history and outcomes of MASLD and MetALD following non-alcoholic fatty liver disease reclassification in a Canadian cohort

Simple item page
dc.catalogadorjlo
dc.contributor.authorAlmahanna, Yousef
dc.contributor.authorIdalsoaga Ferrer, Francisco Javier
dc.contributor.authorDiaz Piga, Luis Antonio
dc.contributor.authorAlmohsen, Ahmed
dc.contributor.authorNong Song, Yi
dc.contributor.authorBajunayd, Amani
dc.contributor.authorMortuza, Rokhsana
dc.contributor.authorKim, Jeemin
dc.contributor.authorAbaya, Adrienne
dc.contributor.authorQasim Khan, Mohammad
dc.contributor.authorArab Verdugo, Juan Pablo
dc.date.accessioned2025-12-04T12:30:57Z
dc.date.available2025-12-04T12:30:57Z
dc.date.issued2025
dc.description.abstractIntroduction and Objectives: Steatotic liver disease (SLD) affects 40 % of North Americans, with some progress-ing to advanced fibrosis. A recent nomenclature update redefined subtypes, distinguishing Metabolic dys-function-associated steatotic liver disease (MASLD), Metabolic and alcohol-associated liver disease (MetALD), and alcohol-associated liver disease (ALD). This study aimed to assess the prevalence of MetALD and ALD in a previously Non-alcoholic fatty liver disease (NAFLD) -labeled cohort, evaluate cardiometabolic risk factors, and analyze short-term outcomes.Materials and Methods: This retrospective observational cohort study included patients referred to a special-ized NAFLD clinic in Ontario, Canada (October 2021−September 2023). Adults (age ≥18 years) with radio-graphic hepatic steatosis were categorized into MASLD, MetALD, or ALD based on gender-specific alcohol consumption thresholds documented in electronic medical records. Baseline characteristics and short-term outcomes were compared across groups.Results: Among 445 patients, MASLD was most prevalent (88.3 %), followed by MetALD (8.9 %) and ALD (2.7 %). Males predominated in MetALD (67.5 %) and ALD (83.4 %) (p = 0.002). Smoking was strongly linked to ALD (p = 0.001). Diabetes was more common in MASLD (32.5 %, p = 0.012), while hypertension and dyslipide- mia showed no significant differences across SLD subtypes. Advanced fibrosis (F3-F4) was present in 16.1 %. In a two-year follow-up, higher mortality incidences were observed in ALD (16.6 %). Additionally, regression of fibrosis was observed across all groups.Conclusions: 11.7 % of patients historically labeled as NAFLD met criteria for MetALD or ALD, underscoring the importance of updated nomenclature. High fibrosis prevalence and ALD-related mortality highlight the need for early screening, precise alcohol assessment, and multidisciplinary care to improve outcomes.
dc.format.extent9 páginas
dc.fuente.origenORCID
dc.identifier.doi10.1016/j.aohep.2025.102166
dc.identifier.urihttps://doi.org/10.1016/j.aohep.2025.102166
dc.identifier.urihttps://repositorio.uc.cl/handle/11534/107253
dc.information.autorucEscuela de Medicina; Idalsoaga Ferrer, Francisco Javier; S/I; 1017394
dc.information.autorucEscuela de Medicina; Diaz Piga, Luis Antonio; 0000-0002-8540-4930; 179253
dc.information.autorucEscuela de Medicina; Arab Verdugo, Juan Pablo; 0000-0002-8561-396X; 132745
dc.language.isoen
dc.nota.accesocontenido parcial
dc.revistaAnnals of Hepatology
dc.rightsacceso restringido
dc.subjectAlcohol-associated liver disease
dc.subjectFibrosis progression
dc.subjectCardiometabolic risk factors
dc.subjectPrevalence
dc.subject.ddc610
dc.subject.ods03 Good health and well-being
dc.subject.odspa03 Salud y bienestar
dc.titleNatural history and outcomes of MASLD and MetALD following non-alcoholic fatty liver disease reclassification in a Canadian cohort
dc.typeartículo
sipa.codpersvinculados1017394
sipa.codpersvinculados179253
sipa.codpersvinculados132745
sipa.trazabilidadORCID;2025-12-01
Files
Collections
Artículos de revistas